相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis
Ioannis Avgerinos et al.
DIABETES OBESITY & METABOLISM (2020)
Study of correlations between metabolic risk factors, PWV and hypertension in college students
Xiaoyi Ji et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2020)
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Hertzel C. Gerstein et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment
Ignatios Ikonomidis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups
Martin Fuechtenbusch et al.
DIABETES OBESITY & METABOLISM (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Dulaglutide inhibits high glucose-induced endothelial dysfunction and NLRP3 inflammasome activation
Xiaojia Luo et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2019)
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
Michael A. Nauck et al.
DIABETES CARE (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
Hiroe Nagaike et al.
DIABETES THERAPY (2019)
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study
Antonino Tuttolomondo et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
Vaia Lambadiari et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes
Makoto Ohara et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
Konstantinos Batzias et al.
JOURNAL OF DIABETES RESEARCH (2018)
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
Katherine R. Tuttle et al.
DIABETES OBESITY & METABOLISM (2017)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
The contributions of fasting and postprandial blood glucose increments to oxidative stress and inflammation in dyslipidemic type 2 diabetic patients with stable ischemic heart disease
Boris Djindjic et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Endothelial function and arterial stiffness indexes in subjects with acute ischemic stroke: Relationship with TOAST subtype
Antonino Tuttolomondo et al.
ATHEROSCLEROSIS (2017)
Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome
Antonino Tuttolomondo et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Correlates of Segmental Pulse Wave Velocity in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study
Michelle L. Meyer et al.
AMERICAN JOURNAL OF HYPERTENSION (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study
J. Miyagawa et al.
DIABETES OBESITY & METABOLISM (2015)
Differential response to endothelial epithelial sodium channel inhibition ex vivo correlates with arterial stiffness in humans
Malte Lenders et al.
JOURNAL OF HYPERTENSION (2015)
Tumour necrosis factor-alpha participates on the endothelin-1/nitric oxide imbalance in small arteries from obese patients: role of perivascular adipose tissue
Agostino Virdis et al.
EUROPEAN HEART JOURNAL (2015)
Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1
Jenny Tong et al.
DIABETES (2014)
Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes
Antonio Ceriello et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Guillermo Umpierrez et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
Carol Wysham et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
Michael Nauck et al.
DIABETES CARE (2014)
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill et al.
ENDOCRINE REVIEWS (2014)
Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
Keith C. Ferdinand et al.
HYPERTENSION (2014)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen M. Dungan et al.
LANCET (2014)
GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production Evidence for Predominance of GLP-2-Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States
Gustavo J. Hein et al.
DIABETES (2013)
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Paul Jellinger et al.
Endocrine Practice (2013)
2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC)
Giuseppe Mancia et al.
JOURNAL OF HYPERTENSION (2013)
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
G. Grunberger et al.
DIABETIC MEDICINE (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species-Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A
Hisko Oeseburg et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study
Naomi M. Hamburg et al.
CIRCULATION (2008)
Early adult risk factor levels and subsequent coronary artery calcification - The CARDIA study
Catherine M. Loria et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Diabetic dyslipidemia
Tina J. Chahil et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2006)
Identification and management of the hypertensive patient with elevated heart rate: Statement of a European Society of Hypertension Consensus Meeting
P Palatini et al.
JOURNAL OF HYPERTENSION (2006)
Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus
JB Meigs et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude
JT Kuvin et al.
AMERICAN HEART JOURNAL (2003)
Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells
Y Anini et al.
ENDOCRINOLOGY (2003)
Insulin causes endothelial dysfunction in humans - Sites and mechanisms
G Arcaro et al.
CIRCULATION (2002)
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
DG Parkes et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Free radicals mediate endothelial dysfunction of coronary arterioles in diabetes
RF Ammar et al.
CARDIOVASCULAR RESEARCH (2000)
分享论文
